

Christoph B Olivier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3863497/publications.pdf>

Version: 2024-02-01

30
papers

417
citations

932766

10
h-index

752256

20
g-index

31
all docs

31
docs citations

31
times ranked

825
citing authors

#	ARTICLE	IF	CITATIONS
1	Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. <i>Basic Research in Cardiology</i> , 2010, 105, 379-387.	2.5	62
2	Role of microparticles in endothelial dysfunction and arterial hypertension. <i>World Journal of Cardiology</i> , 2014, 6, 1135.	0.5	47
3	Triple antithrombotic therapy in cardiac patients: more questions than answers. <i>European Heart Journal</i> , 2014, 35, 216-223.	1.0	32
4	TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran. <i>Thrombosis Research</i> , 2016, 138, 63-68.	0.8	31
5	Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. <i>Clinical Research in Cardiology</i> , 2011, 100, 765-771.	1.5	29
6	Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. <i>Thrombosis and Haemostasis</i> , 2014, 112, 266-272.	1.8	26
7	Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease. <i>JAMA Cardiology</i> , 2019, 4, 7.	3.0	26
8	Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 161-166.	1.0	21
9	Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration. <i>Journal of Pharmacy Practice</i> , 2020, 33, 647-653.	0.5	17
10	P2Y12 receptor blockers are anti-inflammatory drugs inhibiting both circulating monocytes and macrophages including THP-1 cells. <i>Scientific Reports</i> , 2021, 11, 17459.	1.6	14
11	A high ratio of ADP to TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone. <i>Clinical Research in Cardiology</i> , 2014, 103, 968-975.	1.5	10
12	Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. <i>International Journal of Cardiology</i> , 2018, 270, 96-101.	0.8	10
13	Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007604.	1.4	10
14	Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007342.	1.4	10
15	Platelet Bone Morphogenetic Protein-4 Mediates Vascular Inflammation and Neointima Formation after Arterial Injury. <i>Cells</i> , 2021, 10, 2027.	1.8	10
16	Why digital health trials can fail: Lessons learned from a randomized trial of health coaching and virtual cardiac rehabilitation. <i>Cardiovascular Digital Health Journal</i> , 2021, 2, 101-108.	0.5	9
17	MnTBAP increases BMPRII expression in endothelial cells and attenuates vascular inflammation. <i>Vascular Pharmacology</i> , 2016, 84, 67-73.	1.0	8
18	Early platelet dysfunction in patients receiving extracorporeal membrane oxygenation is associated with mortality. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 712-721.	1.0	8

#	ARTICLE	IF	CITATIONS
19	The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count. PLoS ONE, 2016, 11, e0149053.	1.1	7
20	Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel. Journal of Thrombosis and Thrombolysis, 2016, 42, 84-89.	1.0	6
21	The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. Clinical Cardiology, 2019, 42, 797-805.	0.7	4
22	Anticoagulation and anaemia: old opponents from the era of VKA?. European Heart Journal, 2019, 40, 3791-3792.	1.0	4
23	High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting. Journal of Thrombosis and Thrombolysis, 2016, 42, 558-565.	1.0	3
24	Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome. Expert Opinion on Drug Safety, 2018, 17, 251-258.	1.0	3
25	Moderate ischemic mitral regurgitation: coronary artery bypass grafting with versus without simultaneous treatment of the mitral valve. Journal of Cardiovascular Surgery, 2018, 59, 830-835.	0.3	3
26	Dual-Pathway Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention in Stable Coronary Artery Disease: A Single-Center, Single-Operator, Retrospective Cohort Study. Frontiers in Medicine, 2020, 7, 414.	1.2	3
27	Evaluation of Serum Serotonin as a Biomarker for Myocardial Infarction and Ischemia/Reperfusion Injury. Applied Sciences (Switzerland), 2020, 10, 6379.	1.3	2
28	Is Bleeding Always Bad?. Journal of the American College of Cardiology, 2019, 74, 1529-1531.	1.2	1
29	A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation. Journal of Vascular Access, 2020, 21, 467-474.	0.5	1
30	Medical history of coronary artery disease and time to electrocardiogram in the emergency department: a real-life, single-center, retrospective analysis. BMC Cardiovascular Disorders, 2021, 21, 480.	0.7	0